These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 19012670)

  • 21. Paliperidone: quo vadis?
    Citrome L
    Int J Clin Pract; 2007 Apr; 61(4):653-62. PubMed ID: 17343660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets.
    Berwaerts J; Cleton A; Herben V; van de Vliet I; Chang I; van Hoek P; Eerdekens M
    Pharmacopsychiatry; 2009 Jul; 42(4):158-63. PubMed ID: 19585395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment with paliperidone extended-release tablets in a case of resistant undifferentiated schizophrenia: clinical improvement with 12 mg and evaluation through 3TRE scale].
    Rusconi AC; Carlone C; Muscillo M; Piccione M
    Riv Psichiatr; 2009; 44(4):267-72. PubMed ID: 20066799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.
    Emsley R; Berwaerts J; Eerdekens M; Kramer M; Lane R; Lim P; Hough D; Palumbo J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):343-56. PubMed ID: 18854723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials.
    Janicak PG; Wu JH; Mao L
    Curr Med Res Opin; 2008 Jun; 24(6):1807-15. PubMed ID: 18559166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in plasma concentrations of risperidone and 9-hydroxyrisperidone and the associated clinical effects during the switch from oral risperidone to extended-release paliperidone tablets in patients with schizophrenia.
    Yang DS; Seong SJ; Yoon YR; Lim MS; Kwak KH; Lee SJ
    J Psychopharmacol; 2014 Apr; 28(4):341-8. PubMed ID: 24346811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paliperidone (Invega) for schizophrenia.
    Med Lett Drugs Ther; 2007 Mar; 49(1256):21-3. PubMed ID: 17351558
    [No Abstract]   [Full Text] [Related]  

  • 28. Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms.
    Canuso CM; Turkoz I; Sheehan JJ; Bossie CA
    J Affect Disord; 2010 Jan; 120(1-3):193-9. PubMed ID: 19552963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In brief: Injectable paliperidone palmitate for schizophrenia.
    Med Lett Drugs Ther; 2009 Nov; 51(1324):88. PubMed ID: 19890247
    [No Abstract]   [Full Text] [Related]  

  • 30. Paliperidone extended release.
    Yang LP; Plosker GL
    CNS Drugs; 2007; 21(5):417-25; discussion 426-7. PubMed ID: 17447829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paliperidone: An improvement over risperidone?
    Dopheide JA
    Am J Health Syst Pharm; 2008 Mar; 65(5):401. PubMed ID: 18281730
    [No Abstract]   [Full Text] [Related]  

  • 32. Paliperidone-ER: first atypical antipsychotic with oral extended release formulation.
    Lautenschlager M; Heinz A
    Expert Rev Neurother; 2008 Feb; 8(2):193-200. PubMed ID: 18271706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.
    Gopal S; Gassmann-Mayer C; Palumbo J; Samtani MN; Shiwach R; Alphs L
    Curr Med Res Opin; 2010 Feb; 26(2):377-87. PubMed ID: 20001492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release.
    Boom S; Talluri K; Janssens L; Remmerie B; De Meulder M; Rossenu S; van Osselaer N; Eerdekens M; Cleton A
    J Clin Pharmacol; 2009 Nov; 49(11):1318-30. PubMed ID: 19713555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paliperidone extended release: in adolescents with schizophrenia.
    Perry CM
    Paediatr Drugs; 2012 Dec; 14(6):417-27. PubMed ID: 23050744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of paliperidone extended-release in patients with schizophrenia or schizoaffective disorder and hepatic disease.
    Amatniek J; Canuso CM; Deutsch SI; Henderson DC; Mao L; Mikesell C; Rodriguez S; Sheehan J; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Apr; 8(1):8-20. PubMed ID: 23428785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paliperidone-associated atypical neuroleptic malignant syndrome: a case report.
    Han C; Lee SJ; Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):650-1. PubMed ID: 21163319
    [No Abstract]   [Full Text] [Related]  

  • 38. New drug for schizophrenia.
    FDA Consum; 2007; 41(2):6. PubMed ID: 17590895
    [No Abstract]   [Full Text] [Related]  

  • 39. Paliperidone for schizophrenia.
    Dolder C; Nelson M; Deyo Z
    Am J Health Syst Pharm; 2008 Mar; 65(5):403-13. PubMed ID: 18281731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania.
    Canuso CM; Battisti WP
    Expert Opin Pharmacother; 2010 Oct; 11(15):2557-67. PubMed ID: 20854185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.